Delcath Systems, Inc. (DCTH): Price and Financial Metrics

Delcath Systems, Inc. (DCTH): $8.06

0.07 (-0.86%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

C

DCTH Price/Volume Stats

Current price $8.06 52-week high $8.50
Prev. close $8.13 52-week low $2.25
Day low $7.84 Volume 229,300
Day high $8.13 Avg. volume 248,260
50-day MA $6.37 Dividend yield N/A
200-day MA $4.53 Market Cap 223.96M

DCTH Stock Price Chart Interactive Chart >


Delcath Systems, Inc. (DCTH) Company Bio


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.


DCTH Latest News Stream


Event/Time News Detail
Loading, please wait...

DCTH Latest Social Stream


Loading social stream, please wait...

View Full DCTH Social Stream

Latest DCTH News From Around the Web

Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.

Insider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ...

In a notable insider transaction, Chief Medical Officer Vojo Vukovic has recently increased his stake in Delcath Systems Inc (NASDAQ:DCTH) by purchasing 40,000 shares of the company's stock.

Yahoo | December 15, 2023

Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Melanoma Research. The publication, entitled "Quality of Life After Melphalan Hepatic Perfusion for Uveal Melanoma", was based on an independent clinical study conducted by investigators from University Hospital Southampton, UK and focused on the impact of melphalan percutaneous hepatic

Yahoo | December 7, 2023

Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals.

Yahoo | November 15, 2023

Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update

Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023.

Yahoo | November 13, 2023

Delcath Systems to Host Third Quarter 2023 Results Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2023.

Yahoo | November 6, 2023

Read More 'DCTH' Stories Here

DCTH Price Returns

1-mo 2.68%
3-mo 72.22%
6-mo N/A
1-year 44.70%
3-year -22.94%
5-year -90.37%
YTD 93.75%
2023 15.56%
2022 -53.55%
2021 -56.75%
2020 -15.67%
2019 -89.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!